| Mathios M Bayssie, MD | |
|
1265 E College St, Pulaski, TN 38478-4541 | |
| (931) 363-7531 | |
| Not Available |
| Full Name | Mathios M Bayssie |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 11 Years |
| Location | 1265 E College St, Pulaski, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699152686 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 50595 (Kentucky) | Secondary |
| 207Q00000X | Family Medicine | 50595 (Kentucky) | Secondary |
| 207P00000X | Emergency Medicine | 57755 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Southern Tennessee Regional Health System Pulaski | Pulaski, TN | Hospital |
| Macon Community Hospital | Lafayette, TN | Hospital |
| Northcrest Medical Center | Springfield, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency Coverage Corp | 3072412592 | 364 |
| Havely Springs Emergency Group, Pc | 6204298144 | 12 |
News Archive
US schools in poor districts with large non-white student populations are less likely to reopen fully this academic year, according to a major new study published in the peer-reviewed Journal of School Choice.
China Yongxin Pharmaceuticals, Inc., a leading pharmaceutical distributor and chain drugstore operator, today announced financial results for the third quarter ended September 30, 2009.
Nuvilex, Inc., announces today that Legacy Biotechnologies, Inc., its joint venture partner in Reme-Flu™, has commenced production of Reme-Flu™ and expects it to be ready for consumer purchase within the next 30 days. Reme-Flu™ is Legacy Biotechnologies' unique 2-part homeopathic flu remedy designed to help treat symptoms of the flu. Initially, Reme-Flu™ will be offered on the top-rated website, www.nutralegacy.com.
VioQuest Pharmaceuticals today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases.
› Verified 2 days ago
| Entity Name | Emergency Coverage Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427005008 PECOS PAC ID: 3072412592 Enrollment ID: O20050207000666 |
News Archive
US schools in poor districts with large non-white student populations are less likely to reopen fully this academic year, according to a major new study published in the peer-reviewed Journal of School Choice.
China Yongxin Pharmaceuticals, Inc., a leading pharmaceutical distributor and chain drugstore operator, today announced financial results for the third quarter ended September 30, 2009.
Nuvilex, Inc., announces today that Legacy Biotechnologies, Inc., its joint venture partner in Reme-Flu™, has commenced production of Reme-Flu™ and expects it to be ready for consumer purchase within the next 30 days. Reme-Flu™ is Legacy Biotechnologies' unique 2-part homeopathic flu remedy designed to help treat symptoms of the flu. Initially, Reme-Flu™ will be offered on the top-rated website, www.nutralegacy.com.
VioQuest Pharmaceuticals today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases.
› Verified 2 days ago
| Entity Name | App Of Tennessee Ed Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003230236 PECOS PAC ID: 8123251766 Enrollment ID: O20140506000159 |
News Archive
US schools in poor districts with large non-white student populations are less likely to reopen fully this academic year, according to a major new study published in the peer-reviewed Journal of School Choice.
China Yongxin Pharmaceuticals, Inc., a leading pharmaceutical distributor and chain drugstore operator, today announced financial results for the third quarter ended September 30, 2009.
Nuvilex, Inc., announces today that Legacy Biotechnologies, Inc., its joint venture partner in Reme-Flu™, has commenced production of Reme-Flu™ and expects it to be ready for consumer purchase within the next 30 days. Reme-Flu™ is Legacy Biotechnologies' unique 2-part homeopathic flu remedy designed to help treat symptoms of the flu. Initially, Reme-Flu™ will be offered on the top-rated website, www.nutralegacy.com.
VioQuest Pharmaceuticals today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases.
› Verified 2 days ago
| Entity Name | Concord Medical Group Of Kentucky Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346746385 PECOS PAC ID: 9133483894 Enrollment ID: O20191118000999 |
News Archive
US schools in poor districts with large non-white student populations are less likely to reopen fully this academic year, according to a major new study published in the peer-reviewed Journal of School Choice.
China Yongxin Pharmaceuticals, Inc., a leading pharmaceutical distributor and chain drugstore operator, today announced financial results for the third quarter ended September 30, 2009.
Nuvilex, Inc., announces today that Legacy Biotechnologies, Inc., its joint venture partner in Reme-Flu™, has commenced production of Reme-Flu™ and expects it to be ready for consumer purchase within the next 30 days. Reme-Flu™ is Legacy Biotechnologies' unique 2-part homeopathic flu remedy designed to help treat symptoms of the flu. Initially, Reme-Flu™ will be offered on the top-rated website, www.nutralegacy.com.
VioQuest Pharmaceuticals today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases.
› Verified 2 days ago
| Entity Name | Havely Springs Emergency Group, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770090110 PECOS PAC ID: 6204298144 Enrollment ID: O20230809003314 |
News Archive
US schools in poor districts with large non-white student populations are less likely to reopen fully this academic year, according to a major new study published in the peer-reviewed Journal of School Choice.
China Yongxin Pharmaceuticals, Inc., a leading pharmaceutical distributor and chain drugstore operator, today announced financial results for the third quarter ended September 30, 2009.
Nuvilex, Inc., announces today that Legacy Biotechnologies, Inc., its joint venture partner in Reme-Flu™, has commenced production of Reme-Flu™ and expects it to be ready for consumer purchase within the next 30 days. Reme-Flu™ is Legacy Biotechnologies' unique 2-part homeopathic flu remedy designed to help treat symptoms of the flu. Initially, Reme-Flu™ will be offered on the top-rated website, www.nutralegacy.com.
VioQuest Pharmaceuticals today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mathios M Bayssie, MD 1005 Dr. D. B. Todd, Jr., Boulevard, Nashville, TN 37208 Ph: (615) 973-1065 | Mathios M Bayssie, MD 1265 E College St, Pulaski, TN 38478-4541 Ph: (931) 363-7531 |
News Archive
US schools in poor districts with large non-white student populations are less likely to reopen fully this academic year, according to a major new study published in the peer-reviewed Journal of School Choice.
China Yongxin Pharmaceuticals, Inc., a leading pharmaceutical distributor and chain drugstore operator, today announced financial results for the third quarter ended September 30, 2009.
Nuvilex, Inc., announces today that Legacy Biotechnologies, Inc., its joint venture partner in Reme-Flu™, has commenced production of Reme-Flu™ and expects it to be ready for consumer purchase within the next 30 days. Reme-Flu™ is Legacy Biotechnologies' unique 2-part homeopathic flu remedy designed to help treat symptoms of the flu. Initially, Reme-Flu™ will be offered on the top-rated website, www.nutralegacy.com.
VioQuest Pharmaceuticals today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases.
› Verified 2 days ago
Goran Djordje Antic, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1265 E College St, Pulaski, TN 38478 Phone: 931-363-7531 Fax: 865-291-3228 | |
Allen Honig, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1265 E College St, Pulaski, TN 38478 Phone: 931-363-7531 Fax: 865-291-3228 | |
Dr. Matthew Jesse Burns, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1265 E College St, Pulaski, TN 38478 Phone: 931-363-7531 |